Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
J Exp Med. 2019 Sep 2;216(9):1986-1998. doi: 10.1084/jem.20190344. Epub 2019 Jun 24.
IL-6 excess is central to the pathogenesis of multiple inflammatory conditions and is targeted in clinical practice by immunotherapy that blocks the IL-6 receptor encoded by We describe two patients with homozygous mutations in who presented with recurrent infections, abnormal acute-phase responses, elevated IgE, eczema, and eosinophilia. This study identifies a novel primary immunodeficiency, clarifying the contribution of IL-6 to the phenotype of patients with mutations in , and genes encoding different components of the IL-6 signaling pathway, and alerts us to the potential toxicity of drugs targeting the IL-6R.
IL-6 过多是多种炎症性疾病发病机制的核心,临床实践中通过免疫疗法靶向治疗 IL-6 受体,该受体由 编码。我们描述了两名纯合突变患者 ,他们表现为反复感染、异常急性期反应、IgE 升高、湿疹和嗜酸性粒细胞增多。本研究确定了一种新的原发性免疫缺陷,阐明了 IL-6 在 基因突变和编码 IL-6 信号通路不同成分的 基因突变患者表型中的作用,并提醒我们注意靶向 IL-6R 的药物的潜在毒性。